| Literature DB >> 35425367 |
Kandhan Palanisamy1, S M Esther Rubavathy1, Muthuramalingam Prakash1, Ramasamy Thilagavathi2, Maryam S Hosseini-Zare3, Chelliah Selvam3.
Abstract
The recalcitrant spread of the COVID-19 pandemic produced by the novel coronavirus SARS-CoV-2 is one of the most destructive occurrences in history. Despite the availability of several effective vaccinations and their widespread use, this line of immunization often faces questions about its long-term efficacy. Since coronaviruses rapidly change, and multiple SARS-CoV-2 variants have emerged around the world. Therefore, finding a new target-based medication became a priority to prevent and control COVID-19 infections. The main protease (Mpro) is a salient enzyme in coronaviruses that plays a vital role in viral replication, making it a fascinating therapeutic target for SARS-CoV-2. We screened 0.2 million natural products against the Mpro of SARS-CoV-2 using the Universal Natural Product Database (UNPD). As well, we studied the role of ionic liquids (ILs) on the structural stabilization of Mpro. Cholinium-based ILs are biocompatible and used for a variety of biomedical applications. Molecular docking was employed for the initial screening of natural products and ILs against Mpro. To predict the drug-likeness features of lead compounds, we calculated the ADMET properties. We performed MD simulations for the selected complexes based on the docking outcomes. Using MM/PBSA approaches, we conclude that compounds NP-Hit2 (-25.6 kcal mol-1) and NP-Hit3 (-25.3 kcal mol-1) show stronger binding affinity with Mpro. The hotspot residues of Thr25, Leu27, His41, Met49, Cys145, Met165, and Gln189 strongly interacted with the natural compounds. Furthermore, naproxenate, ketoprofenate, and geranate, cholinium-based ILs strongly interact with Mpro and these ILs have antimicrobial properties. Our findings will aid in the development of effective Mpro inhibitors. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35425367 PMCID: PMC8979281 DOI: 10.1039/d1ra08604a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1A) Schematic representation of SARS-CoV-2 and (B) crystal structure of Mpro, blue color indicates the active site of catalytic dyads (i.e., His41 and Cys142).
Fig. 2Virtual screening of natural compounds from Universal Natural Product Database (UNPD).
Fig. 3The virtual screening hits of (A) Natural compounds and (B) Cholinium-based ILs.
Calculated binding energy and H-bond interaction sites of top four Mpro complexes of natural compounds along with the choline-based ILsa
| Selected NP compounds | Docking Score (in kcal mol−1) | H-bonding interactions |
|---|---|---|
| NP-Hit1 | −11.87 | Cys44, Gly143, His164, Asp187, and Gln189 |
| NP-Hit2 | −11.16 | Tyr54, Phe140, Ser144, His163, Glu166, and Asp187 |
| NP-Hit3 | −11.51 | Phe140, Leu141, Asn142, His163, and Arg188 |
| NP-Hit4 | −10.91 | Thr25, Cys44, Phe140, Ser144, His163, Glu166, His172, and Arg188 |
| Choline naproxenate | −10.76 | Lys5, Lys102, Lys137, Asp153, Asp155, and Glu288 |
| Choline ketoprofene | −10.28 | Arg4, Lys5, Lys102, Asp153, Asp155, and Glu288 |
| Choline linoleate | −9.35 | Phe3, Arg4, Lys5, Lys102, Asp153, Asp155, and Glu288 |
| Choline geranate | −9.05 | Lys12, Lys102, Ile152, Asp153 and Asp155 |
The docking score and H-bonding interactions are shown.
Fig. 4Docking conformations of selected natural compounds with Mpro. (A) NP-Hit1 (B) NP-Hit2 (C) NP-Hit3 and (D) NP-Hit4.
Fig. 5Docking conformations of selected choline-based ILs with Mpro. (A) Naproxenate (B) ketoprofenate (C) linoleate (D) geranate and (E) cholinium.
The ADMET properties of natural compounds and cholinium-based ILsa
| Compounds | MW | nHB acceptors | nHB donors | nRotB | nVio | TPSA (Å2) | GI absorption | Heptatoxicity | Carcinogenicity | PAINS |
|---|---|---|---|---|---|---|---|---|---|---|
| NP-Hit1 | 508.4 | 8 | 5 | 3 | 1 | 136.66 | Low | Inactive(0.79) | Inactive(0.58) | 0 |
| NP-Hit2 | 422.4 | 6 | 3 | 3 | 0 | 96.22 | High | Inactive(0.78) | Inactive(0.64) | 0 |
| NP-Hit3 | 363.4 | 5 | 1 | 3 | 0 | 67.45 | High | Inactive(0.81) | Inactive(0.53) | 0 |
| NP-Hit4 | 421.4 | 7 | 6 | 2 | 1 | 124.62 | High | Active(0.69) | Inactive(0.62) | 0 |
| Choline | 104.1 | 1 | 1 | 2 | 0 | 20.23 | Low | Inactive(0.94) | Inactive(0.78) | 0 |
| Naproxenate | 230.2 | 3 | 1 | 3 | 1 | 49.36 | High | Inactive(0.58) | Inactive(0.57) | 0 |
| Ketoprofen | 254.2 | 3 | 1 | 4 | 0 | 54.37 | High | Inactive(0.54) | Inactive(0.75) | 0 |
| Linoleate | 280.4 | 2 | 1 | 14 | 1 | 37.30 | High | Inactive(0.55) | Inactive(0.64) | 0 |
| Geranate | 167.7 | 2 | 0 | 4 | 0 | 40.13 | High | Inactive(0.54) | Inactive(0.79) | 0 |
ADMET properties of MW = molecular weight (g mol−1), nHB donors = number of H-bond donors, nHB acceptors = number of H-bond acceptors, nRotB = number of rotatable bonds, nVio = number of Lipinski's rule violations, TPSA = topological polar surface area, and GI absorption = gastrointestinal absorption.
Fig. 6A) and (C) shows the RMSD and (B) and (D) shows the radius gyration (RR) of complexes of Mpro with natural compounds and choline-based ILs.
Fig. 7The SDF of Mpro with (A) choline naproxenate (B) choline ketoprofen (C) choline linoleate and (D) choline geranate. Blue color denotes the choline cation and red color indicates the various anions.
Fig. 8Calculated MM-PBSA binding free energies of natural compounds with Mpro. vdW = van der Waals, Ele = Electrostatic, Pol = polar solvation, and SASA = solvent accessible surface area are shown.
The calculated ligand–residue interaction energies (in kcal mol−1) of Mpro-natural complexesa
| Residue name | NP-Hit1 | NP-Hit2 | NP-Hit3 | NP-Hit4 |
|---|---|---|---|---|
| Thr25 | −0.89 | −0.27 | −0.34 | −0.77 |
| Leu27 | −0.89 | −0.37 | −1.59 | −0.76 |
| His41 | −1.30 | −0.38 | −0.43 | −1.40 |
| Met49 | −1.35 | −1.42 | −1.32 | −1.61 |
| Cys145 | −0.73 | −0.28 | −1.17 | −0.79 |
| Met165 | −0.58 | −1.68 | −0.59 | −0.29 |
| Gln189 | −0.27 | −1.45 | −0.88 | −0.53 |
The most significant hot spot residues are shown.